Nonhuman Primate Resources

Non-human primates (NHPs) are valuable animal models for biomedical research, especially for studying human diseases and developing new drugs. However, the supply and quality of NHPs for research purposes are often limited by various factors, such as ethical issues, genetic diversity, disease susceptibility, and environmental conditions. To address these challenges and improve the efficiency and reliability of NHP-based drug development, Prisys Biotech and its affiliated units have collaborated to integrate the non-human primate medical research supply chain. They have created a "scientific breeding-scientific utilization" business model that aims to optimize the use of non-human primate biotechnology in drug development.

Prisys Biotech is a notable company in China that specializes in NHP research. Prisys Biotech and its affiliated units has established a large-scale NHP breeding base. The breeding base follows strict standards of animal welfare and biosecurity.

To achieve its goal of creating a high-quality breeding population and generating diverse "industrial application" populations for drug development research, Prisys Biotech has adopted several innovative strategies:

• It has implemented a comprehensive genetic management system that monitors the genetic background, pedigree, health status, and phenotypic traits of each individual NHP in the breeding base. This system ensures the genetic diversity and stability of the breeding population and facilitates the selection of suitable NHPs for specific research purposes.
• It has established a state-of-the-art animal experimental center that provides various services for NHP-based drug development research. These services include preclinical safety evaluation, pharmacokinetics/pharmacodynamics studies, efficacy evaluation, biomarker discovery/validation, and translational medicine. The experimental center is equipped with advanced facilities and instruments, such as PET/CT/MRI scanners, flow cytometers, and gene sequencers, and employs experienced researchers and veterinarians who can conduct high-quality and ethical NHP experiments.
• It has developed several "industrial application" populations that are characterized by specific traits that are relevant for drug development research. These traits include spontaneous diseases (such as diabetes mellitus, obesity, hypertension, atherosclerosis, and Alzheimer's disease), diseases of the elderly and infants (such as osteoporosis, arthritis, menopause, and neonatal sepsis), and biological sample banks (such as serum/plasma/urine samples from healthy or diseased NHPs). These populations provide valuable resources for studying human disease mechanisms and testing new drugs in NHP models.

Through these efforts, Prisys Biotech aims to promote the transformation and application of non-human primate biotechnology in the drug development industry. It also strives to contribute to the advancement of biomedical science and human health.
 

Hot Tags: nonhuman primate resources, research, study, monkey, gene therapy, testing clinical trials, Translational Studies, translational toxicology, testing on primates, Translational, preclinical pharmacology and toxicology